

RESEARCH ARTICLE

# 1,25-Dihydroxyvitamin D Modulates Antibacterial and Inflammatory Response in Human Cigarette Smoke-Exposed Macrophages

Nele Heulens<sup>1</sup>, Hannelie Korf<sup>2</sup>, Carolien Mathyssen<sup>1</sup>, Stephanie Everaerts<sup>1</sup>, Elien De Smidt<sup>2</sup>, Christophe Doods<sup>1</sup>, Jonas Yserbyt<sup>1</sup>, Conny Gysemans<sup>2</sup>, Ghislaine Gayan-Ramirez<sup>1</sup>, Chantal Mathieu<sup>2</sup>, Wim Janssens<sup>1\*</sup>

**1** Laboratory of Respiratory Diseases, Department of Clinical and Experimental Medicine, Katholieke Universiteit Leuven, Leuven, Belgium, **2** Laboratory of Clinical and Experimental Endocrinology, Department of Clinical and Experimental Medicine, Katholieke Universiteit Leuven, Leuven, Belgium

\* [wim.janssens@uzleuven.be](mailto:wim.janssens@uzleuven.be)



## OPEN ACCESS

**Citation:** Heulens N, Korf H, Mathyssen C, Everaerts S, De Smidt E, Doods C, et al. (2016) 1,25-Dihydroxyvitamin D Modulates Antibacterial and Inflammatory Response in Human Cigarette Smoke-Exposed Macrophages. PLoS ONE 11(8): e0160482. doi:10.1371/journal.pone.0160482

**Editor:** Makoto Makishima, Nihon University School of Medicine, JAPAN

**Received:** January 25, 2016

**Accepted:** July 20, 2016

**Published:** August 11, 2016

**Copyright:** © 2016 Heulens et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** This study was funded by FWO Vlaanderen (G.0B11.13) ([www.fwo.be](http://www.fwo.be)), Katholieke Universiteit Leuven (OT/11/088) ([www.kuleuven.be](http://www.kuleuven.be)) and AstraZeneca chair. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have the following interests. This study was partly funded by AstraZeneca chair. There are no patents, products in

## Abstract

Cigarette smoking is associated with increased inflammation and defective antibacterial responses in the airways. Interestingly, vitamin D has been shown to suppress inflammation and to improve antibacterial defense. However, it is currently unknown whether vitamin D may modulate inflammation and antibacterial defects in human cigarette smoke (CS)-exposed airways. To explore these unresolved issues, alveolar macrophages obtained from non-smoking and smoking subjects as well as human cigarette smoke extract (CSE)-treated THP-1 macrophages were stimulated with 1,25-dihydroxyvitamin D (1,25(OH)<sub>2</sub>D) to address inflammatory and antibacterial responses. Although basal levels of inflammatory cytokines and chemokines did not differ between non-smoking and smoking subjects, 1,25(OH)<sub>2</sub>D did reduce levels of IL-6, TNF-α and MCP-1 in alveolar macrophages in response to LPS/IFN-γ, although not statistically significant for TNF-α and IL-6 in smokers. CSE did not significantly alter vitamin D metabolism (expression levels of CYP24A1 or CYP27B1) in THP-1 macrophages. Furthermore, stimulation with 1,25(OH)<sub>2</sub>D reduced mRNA expression levels and/or protein levels of IL-8, TNF-α and MCP-1 in CSE-treated THP-1 macrophages. 1,25(OH)<sub>2</sub>D did not improve defects in phagocytosis of *E. coli* bacteria or the oxidative burst response in CSE-treated THP-1 macrophages or alveolar macrophages from smokers. However, 1,25(OH)<sub>2</sub>D significantly enhanced mRNA expression and/or protein levels of the antimicrobial peptide cathelicidin in alveolar macrophages and THP-1 macrophages, independently of CS exposure. In conclusion, our results provide the first evidence that vitamin D could be a new strategy for attenuating airway inflammation and improving antibacterial defense in CS-exposed airways.

development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. No part of this research has been funded by tobacco industry sources.

## Introduction

In recent years, it has become apparent that the active form of vitamin D, 1,25-dihydroxyvitamin D ( $1,25(\text{OH})_2\text{D}$ ), is not only important for calcium and bone homeostasis, but also exerts important innate immunomodulatory functions [1].  $1,25(\text{OH})_2\text{D}$  has been shown to inhibit the production of inflammatory cytokines and chemokines *in vitro* in response to various inflammatory and/or infectious stimuli [2–5]. In addition to these anti-inflammatory actions,  $1,25(\text{OH})_2\text{D}$  may improve antibacterial defense by stimulating phagocytosis [6–8] as well as by enhancing the production of reactive oxygen species (oxidative burst) [9] and antimicrobial peptides (including cathelicidin) [10,11], which both are important for the efficient killing of bacteria.

Cigarette smoking is a global epidemic and a major risk factor for several life-threatening diseases, including chronic obstructive pulmonary disease (COPD). Alveolar macrophages are crucial in initiating the inflammatory response to cigarette smoke (CS) by releasing inflammatory cytokines and chemokines, such as IL-8 and MCP-1 [12]. This then recruits additional inflammatory cells, including monocytes and neutrophils, to the lungs, which amplifies the inflammatory response. Alveolar macrophages are furthermore important resident phagocytes in the lung, contributing to the clearance of infections [13]. However, CS has been shown to impair antibacterial defense, including the phagocytic uptake of bacteria by macrophages, as demonstrated by *in vitro* as well as *in vivo* animal research [14–19].

Given the anti-inflammatory and antibacterial functions of  $1,25(\text{OH})_2\text{D}$ , it is tempting to speculate that  $1,25(\text{OH})_2\text{D}$  could counteract these effects of CS. However, few studies have suggested that CS could affect vitamin D metabolism by increasing CYP24A1 (24-hydroxylase, catabolizing enzyme that degrades  $1,25(\text{OH})_2\text{D}$ ) [20] or decreasing CYP27B1 ( $1\alpha$ -hydroxylase, activating enzyme leading to formation of  $1,25(\text{OH})_2\text{D}$ ) [21]. As CYP24A1, CYP27B1, but also the vitamin D receptor (VDR) are expressed locally within the lungs [22], such as in alveolar macrophages, these effects of CS on vitamin D metabolism could potentially limit immunomodulatory effects of vitamin D within the respiratory tract. As such, it is still unclear whether  $1,25(\text{OH})_2\text{D}$  modulates pulmonary inflammatory responses and/or antibacterial defects in CS-exposed airways. As macrophages are major players in inflammatory and antibacterial responses in the airways, we investigated the effect of  $1,25(\text{OH})_2\text{D}$  on i) *ex vivo* responses of alveolar macrophages from smoking subjects (compared to non-smoking subjects), and ii) THP-1 macrophages exposed to cigarette smoke extract (CSE).

## Materials and Methods

Experiments involving human samples were approved by the Ethical Committee of University Hospital UZ Leuven (S54148) and all subjects gave informed, written consent.

### Bronchoalveolar lavage (BAL) of non-smoking and smoking subjects

Non-smoking ( $n = 10$ ) and smoking ( $n = 11$ ) subjects, undergoing bronchoscopy for diagnostic reasons, were recruited. Non-smokers were defined as subjects with a normal lung function who never smoked or stopped smoking for more than 5 years, while smokers were defined as subjects with a normal lung function who were current smokers at the moment of BAL sampling ( $34 \pm 5$  pack-years). Normal lung function was defined as forced expiratory volume in 1 second ( $\text{FEV}_1$ )% > 80% and Tiffeneau-index ( $\text{FEV}_1$  over forced vital capacity (FVC;  $\text{FEV}_1/\text{FVC}$ ) > 0.7. Non-smokers and smokers were matched for age (non-smoker:  $66.4 \pm 3.14$  years; smokers:  $59.8 \pm 2.29$  years;  $p = 0.0982$ ) and gender (non-smoker: 60% male; smoker: 64% male;  $p = 0.8639$ ). To reduce bias from bacterial colonization and chronic inflammation, COPD patients were a priori excluded. As a consequence, none of the subjects were taking oral or

inhaled corticosteroids or showed any signs of acute respiratory infection at the moment of BAL sampling. BAL was performed according to standard procedures [23]. BAL consisted of four aliquots of 50 ml sterile saline instilled in the right middle lobe or lingula. BAL samples were filtered and cells were resuspended in culture medium (RPMI 1640 medium-Glutamax supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 µg/ml streptomycin, and 2.5 mg/ml fungizone). Alveolar macrophages were isolated by incubating BAL cells for 2 hours at 37°C to allow adherence of macrophages. Afterwards, non-adherent cells were removed by repeatedly replacing the medium. Alveolar macrophages were stimulated for 48h with  $10^{-8}$ M 1,25(OH)<sub>2</sub>D (Sigma-Aldrich, St-Louis, MO, USA). The dose and exposure time of 1,25(OH)<sub>2</sub>D were based upon literature [24,25]. In certain conditions, alveolar macrophages were additionally stimulated for 24h with a combination of LPS (1 µg/ml) and IFN-γ, (100 IU/ml), a strong inflammatory stimulus [25]. To correct for the different number of alveolar macrophages in each sample, all samples were diluted to  $2 \times 10^6$  cells/ml with culture medium.

### THP-1 macrophages

As the number of BAL samples obtained from non-smoking and smoking subjects was limited, additional experiments were performed on the THP-1 monocytic cell line, differentiated into macrophages, which represent a useful model to study alveolar macrophage responses [26].

**Differentiation and stimulation of THP-1 monocytic cell line.** The THP-1 human acute monocytic leukemia cell line (ATCC, Manassas, VA, USA) was cultured in RPMI medium supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine and 2.5 µg/ml fungizone at 37°C (5% CO<sub>2</sub>). To induce differentiation into adherent macrophages, THP-1 cells were stimulated overnight with phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich) (30 ng/ml) and were allowed to rest for two additional days. THP-1 macrophages were stimulated for 16h with CSE, followed by an additional 24h stimulation with  $10^{-8}$ M 1,25(OH)<sub>2</sub>D (1,25(OH)<sub>2</sub>D post-treatment). For certain experiments, THP-1 macrophages were also pre-treated with 1,25(OH)<sub>2</sub>D (Methods in [S1 File](#)).

**Preparation of CSE.** CSE was generated by bubbling the smoke of 1 cigarette (3R4F research cigarettes, Kentucky Tobacco Research and Development Center, University of Kentucky) through 10 ml of culture medium. The pH was adjusted to 7.4 and CSE was filtered through a 0.2 mm pore filter (Millipore). The resulting solution was considered 100% CSE. CSE was freshly prepared and used within 30 minutes. To ensure standardization between different preparations of CSE, the absorbance was adjusted to OD 0.4 at 340 nm.

**Cytotoxicity.** Cytotoxicity due to CSE exposure was evaluated using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Cells were incubated for 3h with MTT dissolved in HBSS (0.5 mg/ml). The precipitated formazan product was then dissolved in DMSO and absorbance was recorded at a 550 nm wavelength and a reference wavelength of 655 nm. Results are expressed as a percentage of the control values (Figures A and B in [S1 File](#)).

### Inflammatory response

**mRNA and protein levels of inflammatory cytokines and chemokines.** Protein levels of IL-8, TNF-α, MCP-1 and IL-6 were measured in cell-free supernatants of alveolar macrophage and THP-1 macrophage cultures using the Mesoscale Discovery (MSD) technology, according to the manufacturer's instructions. mRNA expression levels of IL-8, TNF-α, MCP-1 and IL-6 in THP-1 macrophages were determined with real-time PCR. Therefore, a constant amount of 1 µg of RNA was reverse transcribed with Superscript III reverse transcriptase (Invitrogen, Life Technologies, Lennik, Belgium). The quantitative PCR amplification reaction was performed

**Table 1. Primers used for quantitative PCR analysis.**

Target	Sequence
GAPDH	<ul style="list-style-type: none"> <li>• 5' -TGGTATCGTGGAAGGACTCA-3' (FW)</li> <li>• 5' -CCAGTAGAGGCAGGGATGAT-3' (RV)</li> </ul>
IL-8	<ul style="list-style-type: none"> <li>• 5' -CATCTTCACTGATTCCTGGATACC-3' (FW)</li> <li>• 5' -TGTCTGGACCCCAAGGAA-3' (RV)</li> </ul>
TNF-α	<ul style="list-style-type: none"> <li>• 5' -TCAGCTTGAGGGTTTGCTAC-3' (FW)</li> <li>• 5' -TGCACTTTGGAGTGATCGG-3' (RV)</li> </ul>
MCP-1	<ul style="list-style-type: none"> <li>• 5' -GCCTCTGCACTGAGATCTTC-3' (FW)</li> <li>• 5' -AGCAGCCACCTTCATTCC-3' (RV)</li> </ul>
IL-6	<ul style="list-style-type: none"> <li>• 5' -TTCTGTGCCTGCAGCTTC-3' (FW)</li> <li>• 5' -GCAGATGAGTACAAAAGTCCTGA-3' (RV)</li> </ul>
Cathelicidin	<ul style="list-style-type: none"> <li>• 5' -GGGCTCCTTTGACATCAGTT-3' (FW)</li> <li>• 5' -AGCAGGGCAAATCTCTTGT -3' (RV)</li> </ul>
VDR	<ul style="list-style-type: none"> <li>• 5' -GATTGGAGAAGCTGGACGAG-3' (FW)</li> <li>• 5' -GTTCTGTGAATGATGGTGA-3' (RV)</li> </ul>
CYP27B1	<ul style="list-style-type: none"> <li>• 5' -CGCACTGTCCCAAGCTG-3' (FW)</li> <li>• 5' -CGGAGCTTGGCAGACATC-3' (RV)</li> </ul>
CYP24A1	<ul style="list-style-type: none"> <li>• 5' -GTGACCATCATCCTCCCAA-3' (FW)</li> <li>• 5' -AGTATCTGCCTCGTGTGTATG-3' (RV)</li> </ul>

FW: forward primer; RV: reverse primer

doi:10.1371/journal.pone.0160482.t001

using a thermal cycler (Eco Real-Time PCR system, Illumina). Primer sequences are shown in [Table 1](#). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as housekeeping gene and data were normalized using the comparative cycle threshold (Ct) method.

## Antibacterial response

**Phagocytosis and oxidative burst.** The phagocytic and oxidative burst capacity was assessed by flow cytometry using an adaptation of the commercial kit BURSTTEST (Orpegen Pharma, Heidelberg, Germany). Briefly, THP-1 macrophages or cells from human BAL samples were incubated for 2 hours at 37°C with *pH*-rodoRed-labeled *E. coli* bacteria (*pH*rodo™ Red *E. coli* Bioparticles® Phagocytosis kit for flow cytometry, Invitrogen), previously opsonized with *E. coli* Bioparticles® opsonizing reagent (Invitrogen). Afterwards, the fluorogenic substrate rhodamine was added for an additional 20 minutes at 37°C. Samples were acquired on a Gallios flow cytometer (Beckman Coulter, Brea, CA, USA) and analyzed with the Kaluza software (Beckman Coulter). For human BAL samples, alveolar macrophages were identified on flow cytometry by staining BAL cells with fluorochrome-labeled monoclonal antibodies against CD11b, CD33 and HLA-DR (eBioscience) for 20 minutes at 4°C.

**mRNA expression levels and protein levels of cathelicidin.** mRNA expression levels of cathelicidin in THP-1 macrophages were determined with real-time PCR, as described above. Primer sequences are shown in [Table 1](#). Levels of cathelicidin in cell-free supernatants of alveolar macrophage and THP-1 macrophage cultures were measured with the human LL-37 ELISA kit (Hycult biotech), according to the manufacturer's instructions.

## mRNA expression levels of proteins in the vitamin D pathway

mRNA expression levels of VDR, CYP27B1 and CYP24A1 in THP-1 macrophages were determined with real-time PCR, as described above. Primer sequences are shown in [Table 1](#).

## Statistical analysis

Data were analyzed using SAS software version 9.3 and are presented as mean±SEM. Differences between groups were analyzed using a two-way ANOVA with a Tukey-Kramer *post-hoc* test for multiple group comparison. A mixed model was applied to account for independent experiments (THP-1 macrophages) or individual patient samples (human alveolar macrophages). Differences were considered significant when p-values were less than 0.05.

## Results

### 1,25(OH)<sub>2</sub>D inhibits *ex vivo* inflammatory responses of alveolar macrophages from both non-smokers and smokers


We aimed to investigate whether 1,25(OH)<sub>2</sub>D influences *ex vivo* inflammatory and/or antibacterial responses of alveolar macrophages from smoking subjects. Therefore, BAL samples were obtained from age- and gender-matched non-smoking and smoking subjects. No differences were observed for basal levels of IL-8, TNF-α, MCP-1 and IL-6 produced by alveolar macrophages from non-smokers or smokers. Treatment with 1,25(OH)<sub>2</sub>D did not alter these basal levels released by alveolar macrophages from non-smoking or smoking subjects (data not shown). However, when alveolar macrophages were additionally stimulated for 24h with a combination of LPS and IFN-γ, a strong inflammatory stimulus, 1,25(OH)<sub>2</sub>D significantly reduced levels of TNF-α, MCP-1 and IL-6 in alveolar macrophages from non-smoking subjects in response to LPS/IFN-γ (Fig 1). Similar trends were observed for alveolar macrophages from smoking subjects, although not statistically significant for levels of TNF-α and IL-6 (Fig 1). No significant differences were observed for levels of IL-8 released by alveolar macrophages from both non-smokers and smokers (Fig 1).

### 1,25(OH)<sub>2</sub>D does not affect *ex vivo* phagocytic or oxidative burst responses, but enhances release of cathelicidin from alveolar macrophages from both non-smoking and smoking subjects

The phagocytic uptake of *E. coli* bacteria was significantly decreased in alveolar macrophages from smokers compared to non-smokers (Fig 2A). The production of reactive oxygen species (oxidative burst) by alveolar macrophages was also decreased in smokers compared to non-smokers, although not reaching statistical significance (Fig 2B). Stimulation with 1,25(OH)<sub>2</sub>D did not significantly alter phagocytic or oxidative burst responses of alveolar macrophages from non-smoking and smoking individuals. In contrast, stimulation with 1,25(OH)<sub>2</sub>D significantly enhanced the release of the antimicrobial peptide cathelicidin from alveolar macrophages to the same extent in both non-smokers and smokers (Fig 2C).

### 1,25(OH)<sub>2</sub>D inhibits the inflammatory response in CSE-treated THP-1 macrophages

As the number of BAL samples obtained from non-smoking or smoking subjects and the number of cells recovered from these samples was limited, a THP-1 macrophage cell line model for alveolar macrophages was used. To investigate whether 1,25(OH)<sub>2</sub>D may affect inflammatory responses in a context of CS exposure, THP-1 macrophages were exposed to 10 or 25% CSE as these CSE concentrations did not induce cytotoxicity (Figure A in S1 File). The effect of 1,25(OH)<sub>2</sub>D treatment on mRNA expression and protein levels of inflammatory cytokines and chemokines was assessed. Post-treatment with 1,25(OH)<sub>2</sub>D significantly reduced mRNA and/or protein levels of IL-8, TNF-α and MCP-1 compared to treatment with 10% CSE alone (Fig 3). Treatment with 1,25(OH)<sub>2</sub>D did not significantly alter protein levels of IL-8 induced by



**Fig 1. Effect of 1,25(OH)<sub>2</sub>D on the *ex vivo* inflammatory response of alveolar macrophages from non-smoking and smoking subjects.** Alveolar macrophages from non-smokers (n = 5) or smokers (n = 5) were stimulated for 48h with 10 nM 1,25(OH)<sub>2</sub>D or vehicle, followed by an additional stimulation for 24h with LPS/IFN- $\gamma$ . Levels of (A) IL-8, (B) TNF- $\alpha$ , (C) MCP-1 and (D) IL-6 were measured in supernatants of alveolar macrophage cultures. mean  $\pm$  SEM. \*p<0.05, \*\*\*p<0.001.

doi:10.1371/journal.pone.0160482.g001

CSE (Fig 3). mRNA and protein levels of IL-6 could not be detected in all conditions. Experiments with 25% CSE showed similar results (data not shown). When pretreating THP-1 cells with 1,25(OH)<sub>2</sub>D prior to 10% CSE exposure, a similar reduction of inflammatory cytokines was also obtained (Fig 4).



## 1,25(OH)<sub>2</sub>D does not improve phagocytic or oxidative burst defects of THP-1 macrophages induced by CSE, but upregulates mRNA and protein levels of cathelicidin


The phagocytic uptake of *E. coli* bacteria or oxidative burst by THP-1 macrophages was significantly decreased after exposure to 25% CSE (Fig 5A and 5B), but not 10% CSE (data not shown). However, 1,25(OH)<sub>2</sub>D did not improve phagocytosis or oxidative burst by THP-1 macrophages exposed to 25% CSE or vehicle (Fig 5A and 5B). On the other hand, 1,25(OH)<sub>2</sub>D significantly increased mRNA and protein levels of cathelicidin in THP-1 macrophages, which was not affected by the exposure to 10% CSE (Fig 4C) or 25% CSE (data not shown). All experiments on THP-1 macrophages were performed with 10% and 25% of CSE. As the results on cytokine release and concomitant suppression by 1,25(OH)<sub>2</sub>D were not different for both concentrations, we reported only the results obtained with 10% of CSE. However, to obtain a significant reduction of phagocytosis capacity 25% CSE was needed, without being toxic to these cells (Figure A in S1 File).

## Exposure to CSE does not alter expression levels of the activating or catabolizing enzyme of 1,25(OH)<sub>2</sub>D in THP-1 macrophages

Finally, we wanted to investigate whether CSE may influence the expression of important proteins in the vitamin D pathway (CYP24A1, CYP27B1 or VDR) and in this way could limit anti-inflammatory or antibacterial actions of 1,25(OH)<sub>2</sub>D within CS-exposed airways. Stimulation with 1,25(OH)<sub>2</sub>D did not affect mRNA expression levels of VDR or CYP27B1, but significantly upregulated expression levels of CYP24A1, a known target for 1,25(OH)<sub>2</sub>D, in THP-1 macrophages (Fig 6). Treatment with 10% CSE did not significantly alter expression levels of CYP27B1 or CYP24A1 in THP-1 macrophages, although VDR expression levels were slightly, but significantly increased following treatment with 10% CSE (Fig 6). Experiments with 25% CSE showed similar results (data not shown).


## Discussion

*In vitro* research has demonstrated important antibacterial functions as well as anti-inflammatory effects of 1,25(OH)<sub>2</sub>D in response to different inflammatory stimuli. However, currently,



**Fig 2. Effect of 1,25(OH)<sub>2</sub>D on ex vivo antibacterial response of alveolar macrophages from non-smoking and smoking subjects.** Alveolar macrophages from non-smokers or smokers were stimulated for 48h with 10 nM 1,25(OH)<sub>2</sub>D or vehicle. (A) Phagocytosis and (B) oxidative burst by alveolar macrophages from non-smokers (n = 7) and smokers (n = 11) following bacterial challenge. Graphs show the percentage of alveolar macrophages that have internalized *E. coli* bacteria (A) or have produced reactive oxygen species (B). (C) Cathelicidin levels were measured in supernatants of alveolar macrophage cultures from non-smokers (n = 5) and smokers (n = 5). mean±SEM. \*p<0.05, \*\*p<0.01.

doi:10.1371/journal.pone.0160482.g002






**Fig 3. Effect of 1,25(OH)<sub>2</sub>D on the inflammatory response in CSE-treated THP-1 macrophages.** THP-1 macrophages were stimulated for 16h with 10% CSE or vehicle, followed by an additional stimulation for 24h with 10 nM 1,25(OH)<sub>2</sub>D or vehicle. mRNA and protein levels of (A) IL-8, (B) TNF- $\alpha$  and (C) MCP-1 were determined in cell lysates and culture supernatants, respectively. Independent experiments were performed in triplicate. mean $\pm$ SEM. \* $p$ <0.05, \*\* $p$ <0.01, \*\*\* $p$ <0.0001.

doi:10.1371/journal.pone.0160482.g003

it is not known whether vitamin D could influence inflammation and antibacterial defects in CS-exposed airways. As alveolar macrophages play a major role in innate immune processes within the respiratory system [12,13], we investigated in the present study whether 1,25(OH)<sub>2</sub>D may affect *ex vivo* responses of alveolar macrophages from smoking individuals. Unexpectedly, no differences were observed in baseline release of inflammatory mediators between alveolar macrophages from smokers and non-smokers, which may correlate with the low-grade baseline inflammation observed in the enrolled subjects, in whom COPD and other inflammatory pulmonary disease was excluded. To compare effects of 1,25(OH)<sub>2</sub>D on inflammatory responses between smoking and non-smoking subjects, alveolar macrophages were additionally stimulated with a strong inflammatory stimulus, a combination of LPS and IFN- $\gamma$ , [25]. Interestingly, 1,25(OH)<sub>2</sub>D inhibited the release of pro-inflammatory cytokines (TNF- $\alpha$ , MCP-1 and IL-6) by alveolar macrophages from both non-smokers and smokers in response to LPS/IFN- $\gamma$  stimulation. These results extend the idea that the anti-inflammatory potential of vitamin D in healthy individuals may also persist in smokers. However, due to small sample size, caution should be taken with general conclusions regarding our *ex vivo* data. In particular, the use of different concentrations of 1,25(OH)<sub>2</sub>D exposure but also different exposure times may possibly lead to slightly different results. To overcome the problem of a limited number of available macrophages per sample, we used PMA-stimulated THP-1 cells, which represent a useful model to study alveolar macrophage responses and which were previously shown to maintain a normal vitamin D metabolism [26,27]. In THP-1 macrophages, treatment with 1,25(OH)<sub>2</sub>D significantly reduced mRNA and/or protein levels of IL-8, TNF- $\alpha$  and MCP-1 in response to CSE. These results are in line with previous reports demonstrating the downregulation of pro-inflammatory cytokine production by 1,25(OH)<sub>2</sub>D in innate immune cells in response to inflammatory signals other than CS. In monocytes/macrophages, 1,25(OH)<sub>2</sub>D reduced the production of TNF- $\alpha$  and/or IL-6 in response to LPS by inhibiting NF- $\kappa$ B and p38 MAPK activity [2,5]. Moreover, Hansdottir and colleagues demonstrated that vitamin D attenuated the induction of IL-8 mRNA by viral mimetic poly(I:C) in airway epithelial cells [4]. Similarly, Golden and colleagues found that 1,25(OH)<sub>2</sub>D reduced IL-8 release by human bronchial epithelial cells and human peripheral blood monocytes induced by organic dust [3]. By lowering levels of cytokines and chemokines in response to CS, 1,25(OH)<sub>2</sub>D may indirectly reduce infiltration of inflammatory cells, including macrophages and neutrophils, into the airways and in this way downregulate the airway inflammatory response. Interestingly, in an animal model of acute lung injury, it has already been shown that intratracheal or peroral administration of 1,25(OH)<sub>2</sub>D inhibits the recruitment of neutrophils after LPS inhalation [28].

CS has been shown to impair antibacterial defense. *In vitro*, exposure to CSE reduced the phagocytic capacity of both macrophages and neutrophils [14,19]. Furthermore, we have previously shown that CS exposure of mice results in reduced *ex vivo* phagocytic and oxidative burst responses of alveolar macrophages in the BAL fluid [29]. In this study, we confirm that CS impairs antibacterial defense, as the phagocytic uptake of *E. coli* bacteria was significantly decreased in alveolar macrophages obtained from smoking subjects compared to non-smoking subjects. Similar trends were observed for the oxidative burst capacity of alveolar macrophages, although not statistically significant. Consistent with these results, both the phagocytic and oxidative burst capacity of THP-1 macrophages was reduced by exposure to CSE. These defects in




**Fig 4. Effect of pre-treatment with 1,25(OH)<sub>2</sub>D on the inflammatory response of CSE-treated THP-1 macrophages.** THP-1 macrophages were stimulated for 24h with 10 nM 1,25(OH)<sub>2</sub>D or vehicle, followed by an additional 16h stimulation with 10% CSE or vehicle. mRNA and protein levels of (A) IL-8, (B) TNF- $\alpha$  and (C) MCP-1 were determined in cell lysates and culture supernatants, respectively. Independent experiments were performed in triplicate. mean $\pm$ SEM. \* $p$ <0.05, \*\* $p$ <0.01, \*\*\* $p$ <0.001, \*\*\*\* $p$ <0.0001.

doi:10.1371/journal.pone.0160482.g004

the antibacterial functionality of macrophages may explain why cigarette smokers are more susceptible to respiratory infections [30]. However, in both human alveolar macrophages or THP-1 macrophages, 1,25(OH)<sub>2</sub>D did not significantly alter the phagocytic or oxidative burst capacity. In contrast to these findings, previous *in vitro* studies have demonstrated that 1,25(OH)<sub>2</sub>D can improve the phagocytic capacity as well as the oxidative burst functions of monocytes [6–9]. These effects of 1,25(OH)<sub>2</sub>D on monocyte antibacterial functions are potentially explained by the prodifferentiating effects of 1,25(OH)<sub>2</sub>D on monocytes, which adopt a more mature phenotype [6,22]. In addition, some of these studies have been performed with different cells (including P388D1 and phagocytic cells obtained from normal human peripheral blood). Although the dose used in our study (10<sup>-8</sup>M) was in the range that has been shown to have an effect on phagocytic capacity and oxidative burst, the different outcome may be explained by the use of different cell types. The effect of CSE on phagocytosis and oxidative burst was only clear when we used a CSE of 25% instead of the 10% reported for all other experiments with THP-1 cells. This generates the interesting hypothesis that the decrease in phagocytosis and oxidative burst only present at high levels of CSE could correlate with increased bronchial infections in heavy vs light smokers. However, to our current knowledge there are no reports in human of impaired macrophage function caused by cigarette smoke and its subsequent risk for infection. Although 1,25(OH)<sub>2</sub>D did not affect phagocytic or oxidative burst antibacterial functions, 1,25(OH)<sub>2</sub>D treatment significantly increased levels of the antimicrobial peptide cathelicidin released by alveolar macrophages from both smoking and non-smoking individuals. Consistently, we demonstrated that 1,25(OH)<sub>2</sub>D upregulates mRNA and protein levels of cathelicidin in THP-1 macrophages, independent of CSE exposure. Upregulation of cathelicidin by 1,25(OH)<sub>2</sub>D has been demonstrated in several cell types, including macrophages and neutrophils, and has shown to be crucial in the intracellular killing of *Mycobacterium tuberculosis* [10,11]. Moreover, cathelicidin exerts bactericidal activity to a broad spectrum of bacteria, including both Gram-positive and Gram-negative bacteria by disrupting bacterial membranes. Therefore, our results from both alveolar macrophages and THP-1 macrophages suggest that 1,25(OH)<sub>2</sub>D could improve antibacterial defense, also in a CS environment by upregulating cathelicidin, however, without affecting bacterial uptake or oxygen-dependent intracellular killing.


There are a few limitations of our study that need to be mentioned. Firstly, antibacterial defense was only assessed by measuring phagocytosis and oxidative burst following challenge with *E. coli* bacteria and mRNA expression and/or protein levels of cathelicidin. Although our data provide the first evidence of the antibacterial potential of 1,25(OH)<sub>2</sub>D in CS-exposed macrophages, it still needs to be explored whether the upregulation of cathelicidin also results in the effective clearance of more relevant bacterial species causing respiratory tract infections, such as nontypeable *Haemophilus influenzae* and *Streptococcus pneumoniae*, in cultures of CS-exposed cells using bactericidal assays. Secondly, the number of BAL samples and the number of cells recovered from these samples was limited. Therefore, not all outcomes could be assessed in cultures of human alveolar macrophages (e.g. mRNA expression levels of inflammatory mediators or proteins in the vitamin D pathway). Moreover, because of large variation between different human BAL samples, statistical significance was not always reached. Finally, we used CSE of which the physiological relevance in terms of tobacco smoke exposure is hard



**Fig 5. Effect of 1,25(OH)<sub>2</sub>D on antibacterial response in CSE-treated THP-1 macrophages.** THP-1 macrophages were stimulated for 16h with 10% or 25% CSE or vehicle, followed by an additional stimulation for 24h with 10 nM 1,25(OH)<sub>2</sub>D or vehicle. (A) Phagocytosis and (B) oxidative burst by THP-1 macrophages following bacterial challenge. Graphs show the percentage of alveolar macrophages that have internalized *E. coli* bacteria (A) or have produced reactive oxygen species (B). (C) mRNA and protein levels of cathelicidin were determined in cell lysates and culture supernatants, respectively. Independent experiments were performed in triplicate. mean±SEM. \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001.

doi:10.1371/journal.pone.0160482.g005

to interpret. Although we standardized the extracts to 10 or 25% concentrations based upon optical density, it is also hard to compare them with concentrations used in other studies.



**Fig 6. Effect of CSE on vitamin D metabolism in THP-1 macrophages.** THP-1 macrophages were stimulated for 16h with 10% CSE or vehicle, followed by an additional stimulation for 24h with 10 nM 1,25(OH)<sub>2</sub>D or vehicle. mRNA expression levels of (A) VDR, (B) CYP27B1 and (C) CYP24A1 were determined in cell lysates. mean±SEM. \*p<0.05, \*\*\*p<0.001

doi:10.1371/journal.pone.0160482.g006

A few studies have suggested that CS exposure may interfere with vitamin D metabolism and in this way with immunomodulatory functions of vitamin D within the respiratory tract. In this context, Mulligan *et al.* demonstrated that CSE downregulated CYP27B1 expression in control human sinonasal epithelial cells, leading to less conversion of 25OHD to 1,25(OH)<sub>2</sub>D [21]. Moreover, benzopyrene, a constituent of CS, was shown to enhance the 1,25(OH)<sub>2</sub>D-dependent induction of CYP24A1 in THP-1 cells [20]. In contrast, we did not find significant effects of CSE on expression levels of important proteins in the vitamin D pathway (VDR, CYP27B1 and CYP24A1) in THP-1 macrophages. In addition, preliminary data show no significant difference in CYP27B1 or CYP24A1 expression between the alveolar macrophages of non-smokers and smokers (data not shown). Although these findings should be confirmed in primary cells like respiratory epithelial cells from smoking subjects, our results suggest that vitamin D may provide a new strategy for attenuating inflammation and improving antibacterial defense in CS-exposed airways. Although our study did not specifically address the inflammation related to COPD, it is tempting to discuss our findings in the context of COPD, where CS exposure and vitamin D deficiency are strongly associated [22,31]. Moreover, different studies have demonstrated an accelerated decline of lung function (forced expiratory volume in 1 second, FEV1) and increased likelihood for COPD onset in smokers with vitamin D deficiency [32,33]. At this stage, there are no data showing that optimization of vitamin D status may prevent COPD onset, but two randomized placebo-controlled intervention trials have shown benefit of vitamin D supplementation in COPD patients with vitamin D deficiency with regard to exacerbations [34,35]. Therefore, our *in vitro* research may indirectly suggest that vitamin D supplementation, through the attenuation of macrophage-driven inflammation and the upregulation of cathelicidin levels, may reduce the risk of respiratory infections and COPD in smokers.

## Supporting Information

**S1 File. Supplementary methods and results.**  
(DOCX)

## Acknowledgments

The authors would like to thank David Demedts and Kristien De Bent for their assistance.

## Author Contributions

**Conceptualization:** NH WJ.

**Data curation:** NH WJ.

**Formal analysis:** NH HK C. Mathysen SE.

**Funding acquisition:** HK WJ.

**Investigation:** NH HK ED.

**Methodology:** NH HK C. Mathysen SE CD JY GGR.

**Project administration:** HK WJ.

**Resources:** WJ.

**Supervision:** CG C. Mathieu GGR WJ.

**Visualization:** NH WJ.

**Writing - original draft:** NH HK C. Mathysen SE ED.

**Writing - review & editing:** CD JY CG C. Mathieu GGR WJ.

## References

1. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. *Curr Opin Pharmacol*. 2010; 10:482–96. doi: [10.1016/j.coph.2010.04.001](https://doi.org/10.1016/j.coph.2010.04.001) PMID: [20427238](https://pubmed.ncbi.nlm.nih.gov/20427238/)
2. Cohen-Lahav M, Shany S, Tobvin D, Chaimovitz C, Douvdevani A. Vitamin D decreases NF-kappaB activity by increasing IkappaBalpha levels. *Nephrol Dial Transplant*. 2006; 21:889–97. PMID: [16455676](https://pubmed.ncbi.nlm.nih.gov/16455676/)
3. Golden GA, Wyatt TA, Romberger DJ, Reiff D, McCaskill M, Bauer C, et al. Vitamin D treatment modulates organic dust-induced cellular and airway inflammatory consequences. *J Biochem Mol Toxicol*. 2013; 27:77–86. doi: [10.1002/jbt.21467](https://doi.org/10.1002/jbt.21467) PMID: [23281135](https://pubmed.ncbi.nlm.nih.gov/23281135/)
4. Hansdottir S, Monick MM, Lohan N, Powers L, Gerke A, Hunninghake GW. Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state. *J Immunol*. 2010; 184(2):965–74. doi: [10.4049/jimmunol.0902840](https://doi.org/10.4049/jimmunol.0902840) PMID: [20008294](https://pubmed.ncbi.nlm.nih.gov/20008294/)
5. Zhang Y, Leung DYM, Richers BN, Liu Y, Remigio LK, Riches DW, et al. Vitamin D Inhibits Monocyte/Macrophage Proinflammatory Cytokine Production by Targeting MAPK Phosphatase-1. *J Immunol*. 2012; 188:2127–35. doi: [10.4049/jimmunol.1102412](https://doi.org/10.4049/jimmunol.1102412) PMID: [22301548](https://pubmed.ncbi.nlm.nih.gov/22301548/)
6. Goldman R. Induction of a high phagocytic capability in P388D1, a macrophage-like tumor cell line, by 1alpha,25-dihydroxyvitamin D3. *Cancer Res*. 1984; 44:11–9. PMID: [6546302](https://pubmed.ncbi.nlm.nih.gov/6546302/)
7. Tokuda N, Levy R. 1,25-dihydroxyvitamin D3 stimulates phagocytosis but suppresses HLA-DR and CD13 antigen expression in human mononuclear phagocytes. *Proc Soc Exp Biol Med*. 1996; 211:244–50. PMID: [8633104](https://pubmed.ncbi.nlm.nih.gov/8633104/)
8. Xu H, Soruri A, Gieleseler R, Peters J. 1,25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity, and phagocytosis of human monocytes. *Scand J Immunol*. 1993; 38:535–40. PMID: [8256111](https://pubmed.ncbi.nlm.nih.gov/8256111/)
9. Sly LM, Lopez M, Nauseef WM, Reiner NE. 1alpha,25-Dihydroxyvitamin D3-induced Monocyte Antimicrobial Activity is Regulated by Phosphatidylinositol 3-Kinase and Mediated by the NADPH-dependent Phagocyte Oxidase. *J Biol Chem*. 2001; 276:35482–93. PMID: [11461902](https://pubmed.ncbi.nlm.nih.gov/11461902/)
10. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Wu K, et al. Toll-Like Receptor Triggering of a Vitamin-D-Mediated Human Antimicrobial Response. *Science* (80-). 2006; 311:23–6.
11. Wang T-T, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting Edge: 1,25-Dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. *J Immunol*. 2004; 173:2909–12. PMID: [15322146](https://pubmed.ncbi.nlm.nih.gov/15322146/)
12. Barnes PJ. Cellular and Molecular Mechanisms of Chronic Obstructive Pulmonary Disease. *Clin Chest Med*. 2014 Mar; 35:71–86. doi: [10.1016/j.ccm.2013.10.004](https://doi.org/10.1016/j.ccm.2013.10.004) PMID: [24507838](https://pubmed.ncbi.nlm.nih.gov/24507838/)



13. Dockrell D, Collini P, Marriott H. Alveolar macrophages in: *Mucosal Immunology of Acute Bacterial Pneumonia*. 2012;1–48.
14. Bozinovski S, Vlahos R, Zhang Y, Lah LC, Seow HJ, Mansell A, et al. Carbonylation caused by cigarette smoke extract is associated with defective macrophage immunity. *Am J Respir Cell Mol Biol*. 2011; 45:229–36. doi: [10.1165/rcmb.2010-0272OC](https://doi.org/10.1165/rcmb.2010-0272OC) PMID: [20935190](https://pubmed.ncbi.nlm.nih.gov/20935190/)
15. Harvey CJ, Thimmulappa RK, Sethi S, Kong X, Yarmus L, Brown RH, et al. Targeting Nrf2 Signaling Improves Bacterial Clearance by Alveolar Macrophages in Patients with COPD and in a Mouse Model. *Sci Transl Med*. 2011;(78):78ra32. doi: [10.1126/scitranslmed.3002042](https://doi.org/10.1126/scitranslmed.3002042) PMID: [21490276](https://pubmed.ncbi.nlm.nih.gov/21490276/)
16. Mehta H, Nazzari K, Sadikot RT. Cigarette smoking and innate immunity. *Inflamm Res*. 2008; 57:497–503. doi: [10.1007/s00011-008-8078-6](https://doi.org/10.1007/s00011-008-8078-6) PMID: [19109742](https://pubmed.ncbi.nlm.nih.gov/19109742/)
17. Ortega E, Barriga C, Rodríguez AB. Decline in the phagocytic function of alveolar macrophages from mice exposed to cigarette smoke. *Comp Immunol Microbiol Infect Dis*. 1994 Feb; 17:77–84. PMID: [8004937](https://pubmed.ncbi.nlm.nih.gov/8004937/)
18. Phipps JC, Aronoff DM, Curtis JL, Goel D, O'Brien E, Mancuso P. Cigarette smoke exposure impairs pulmonary bacterial clearance and alveolar macrophage complement-mediated phagocytosis of *Streptococcus pneumoniae*. *Infect Immun*. 2010; 78:1214–20. doi: [10.1128/IAI.00963-09](https://doi.org/10.1128/IAI.00963-09) PMID: [20008540](https://pubmed.ncbi.nlm.nih.gov/20008540/)
19. Stringer KA, Tobias M, O'Neill HC, Franklin CC. Cigarette smoke extract-induced suppression of caspase-3-like activity impairs human neutrophil phagocytosis. *Am J Physiol Lung Cell Mol Physiol*. 2007; 292:L1572–9. PMID: [17351060](https://pubmed.ncbi.nlm.nih.gov/17351060/)
20. Matsunawa M, Amano Y, Endo K, Uno S, Sakaki T, Yamada S, et al. The aryl hydrocarbon receptor activator benzo[a]pyrene enhances vitamin D3 catabolism in macrophages. *Toxicol Sci*. 2009; 109:50–8. doi: [10.1093/toxsci/kfp044](https://doi.org/10.1093/toxsci/kfp044) PMID: [19244278](https://pubmed.ncbi.nlm.nih.gov/19244278/)
21. Mulligan JK, Nagel W, O'Connell BP, Wentzel J, Atkinson C, Schlosser RJ. Cigarette smoke exposure is associated with vitamin D3 deficiencies in patients with chronic rhinosinusitis. *J Allergy Clin Immunol*. 2014 Aug; 134:342–9. doi: [10.1016/j.jaci.2014.01.039](https://doi.org/10.1016/j.jaci.2014.01.039) PMID: [24698317](https://pubmed.ncbi.nlm.nih.gov/24698317/)
22. Heulens N, Korf H, Janssens W. Innate immune modulation in chronic obstructive pulmonary disease: moving closer toward vitamin D therapy. *J Pharmacol Exp Ther*. 2015; 353:360–8. doi: [10.1124/jpet.115.223032](https://doi.org/10.1124/jpet.115.223032) PMID: [25755208](https://pubmed.ncbi.nlm.nih.gov/25755208/)
23. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group. *Eur Respir J*. 1989; 2:561–85. PMID: [2663535](https://pubmed.ncbi.nlm.nih.gov/2663535/)
24. Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: vitamin D-mediated human antimicrobial activity against *Mycobacterium tuberculosis* is dependent on the induction of cathelicidin. *J Immunol*. 2007; 179(4):2060–3. PMID: [17675463](https://pubmed.ncbi.nlm.nih.gov/17675463/)
25. Korf H, Wenes M, Stijlemans B, Takiishi T, Robert S, Miani M, et al. 1,25-Dihydroxyvitamin D3 curtails the inflammatory and T cell stimulatory capacity of macrophages through an IL-10-dependent mechanism. *Immunobiology*. 2012; 217:1292–300. doi: [10.1016/j.imbio.2012.07.018](https://doi.org/10.1016/j.imbio.2012.07.018) PMID: [22944250](https://pubmed.ncbi.nlm.nih.gov/22944250/)
26. Daigneault M, Preston JA, Marriott HM, Whyte MKB, Dockrell DH. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. *PLoS One*. 2010; 5:e8668. doi: [10.1371/journal.pone.0008668](https://doi.org/10.1371/journal.pone.0008668) PMID: [20084270](https://pubmed.ncbi.nlm.nih.gov/20084270/)
27. Dusso A, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, et al. Gamma-Interferon-induced resistance to 1,25-(OH)<sub>2</sub>D<sub>3</sub> in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. *J Clin Endocrinol Metab*. 1997; 82:2222–32. PMID: [9215298](https://pubmed.ncbi.nlm.nih.gov/9215298/)
28. Takano Y, Mitsuhashi H, Ueno K. 1α,25-Dihydroxyvitamin D<sub>3</sub> inhibits neutrophil recruitment in hamster model of acute lung injury. *Steroids*. 2011; 76:1305–9. doi: [10.1016/j.steroids.2011.06.009](https://doi.org/10.1016/j.steroids.2011.06.009) PMID: [21745487](https://pubmed.ncbi.nlm.nih.gov/21745487/)
29. Heulens N, Korf H, Cielien N, De Smidt E, Maes K, Gysemans C, et al. Vitamin D deficiency exacerbates COPD-like characteristics in the lungs of cigarette smoke-exposed mice. *Respir Res*. 2015; 16.
30. Arcavi L, Benowitz NL. Cigarette smoking and infection. *Arch Intern Med*. 2004; 164:2206–16. PMID: [15534156](https://pubmed.ncbi.nlm.nih.gov/15534156/)
31. Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buyschaert I, et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. *Thorax*. 2010; 65:215–20. doi: [10.1136/thx.2009.120659](https://doi.org/10.1136/thx.2009.120659) PMID: [19996341](https://pubmed.ncbi.nlm.nih.gov/19996341/)
32. Afzal S, Lange P, Bojesen SE, Freiberg JJ, Nordestgaard BG. Plasma 25-hydroxyvitamin D, lung function and risk of chronic obstructive pulmonary disease. *Thorax*. 2014; 69:24–31. doi: [10.1136/thoraxjnl-2013-203682](https://doi.org/10.1136/thoraxjnl-2013-203682) PMID: [23908128](https://pubmed.ncbi.nlm.nih.gov/23908128/)
33. Lange NE, Sparrow D, Vokonas P, Litonjua AA. Vitamin D deficiency, smoking, and lung function in the Normative Aging Study. *Am J Respir Crit Care Med*. 2012; 186:616–21. doi: [10.1164/rccm.201110-1868OC](https://doi.org/10.1164/rccm.201110-1868OC) PMID: [22822023](https://pubmed.ncbi.nlm.nih.gov/22822023/)

34. Lehouck A, Mathieu C, Carremans C, Baeke F, Verhaegen J, Eldere J Van, et al. High Doses of Vitamin D to Reduce Exacerbations in Chronic Obstructive Pulmonary Disease. *Ann Intern Med*. 2012; 156:105–14. doi: [10.7326/0003-4819-156-2-201201170-00004](https://doi.org/10.7326/0003-4819-156-2-201201170-00004) PMID: [22250141](https://pubmed.ncbi.nlm.nih.gov/22250141/)
35. Martineau AR, James WY, Hooper RL, Barnes NC, Jolliffe D a, Greiller CL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial. *Lancet Respir Med*. 2015; 3:120–30. doi: [10.1016/S2213-2600\(14\)70255-3](https://doi.org/10.1016/S2213-2600(14)70255-3) PMID: [25476069](https://pubmed.ncbi.nlm.nih.gov/25476069/)